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Letters
RESEARCH LETTER
A Comparison of Payments to a For-Profit Dialysis
Firm FromGovernment and Commercial Insurers
Between 1996 and 2016, the number of people receiving
dialysis in the United States increased by 4.3% annually.1
Dialysis is expensive, but typical cost analyses focus on
Medicare1,2 and ignore the contributionsof commercial insur-
ers. The national dialysis market is controlled by 2 for-profit
organizations, one of which—DaVita—operates 37% of the
market.3 Because this company generates revenues almost
exclusively from dialysis and itemizes revenues by payer, we
are able to assess differences in payments from government
andcommercial insurers todialysis clinics throughanalysis of
this company’s financial records.
Methods |Annual financial statementsofDaVita Inc fromJanu-
ary2010throughDecember2017were retrievedonline.3These
reports aremandatedby theUSSecurities andExchange com-
mission, undergo independent audit, and are verified by the
chief executive officer. Analyses were limited to the “US
dialysis and related lab services” segment, representing 86%
of the company’s net revenue. This segment includes outpa-
tient hemodialysis (representing 79% of the segment’s rev-
enue), outpatient peritoneal dialysis (16%), and inpatient
dialysis (5%). The company itemizes revenues and expenses
for the segment but not for the subsegments.
Volume and financial data were extracted and summa-
rized. Volume measures included the number of clinics, esti-
matedannualnumberofpatients, andannualnumberof treat-
ments. Financial data included net revenue (ie, actual
reimbursement), expenses, and operating income, and were
updated to2017USdollarsusing themedical componentof the
consumerprice index.Revenueswerestratifiedasgovernment-
based (primarily Medicare and Medicaid) or commercial.
Revenue to the company represents costs to payers, expenses
are costs to the company of delivering the service, and operat-
ing income (revenueminus expenses) is the pretax profit.
Results | As of December 2017, the company owned and oper-
ated 2510 clinics throughout the United States. In 2017, total
estimated patient volume was 197 800 and annual treat-
ments were 28.3 million. Total revenue for the dialysis and
laboratory services segment was $9.36 billion, equating to
$47 321 per patient-year or $331 per treatment (Table).
Commercial payers represented 10.5% of volume but gener-
ated 33% of revenue. As a result, government revenues aver-
aged $35424per patient-year or $248per treatment,whereas
commercial revenues averaged $148 722 per patient-year or
$1041 per treatment. Reportedmean expenseswere $269 per
treatment, resulting in a mean pretax operating income of
$63 (19%) per treatment.
Between 2010 and 2017, patient volume increased from
125000to197800(6.8%annualgrowth),andannualtreatments
increasedfrom18.0millionto28.3million(6.7%annualgrowth).
Overthisperiod,thecompany’srevenuemixremainedrelatively
stable (34% commercial in 2010 and 33% in 2017), mean pay-
mentsdeclined frombothgovernmentandcommercialpayers;
however, operating income showed little variation owing to
comparable decreases inmean expenses (Figure).
Discussion | In 2017, commercial insurers paid one of the larg-
estdialysis suppliers4 times therateof theirgovernmentpeers.
Table. DaVita Inc Revenue, Expenses, and Operating Income for Dialysis
Services, Including per Patient and per Treatment, in Calendar Year 2017
Total, $ Per Patient, $ Per Treatment, $
Revenue
Total net 9 360 000 000 47 321 331
Government 6 271 200 000 35 424 248
Commercial 3 088 800 000 148 722 1041
Total expenses 7 592 000 000 38 382 269
Operating income 1 768 000 000 8938 63
Revenue for government and nongovernment payers was estimated by
multiplying total net revenue by 67% and 33%, respectively, whereas the
patient and treatment denominators were generated bymultiplying the total
number of patients and treatments by 89.5% and 10.5%, respectively. These
proportions were provided in the text of the 2017 financial statement.
Figure. Changes in Per-Treatment Revenue, Expenses, and Operating
Income Between 2010 and 2017
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All values were updated to 2017 US dollars using themedical component of the
consumer price index. Expenses and operating incomewere taken directly from
the financial statement. Revenue stratified by payer (commercial vs
government) was calculated using proportions provided in the financial
statement related to volume and revenue from each payer.
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Compared with their nonprofit analogs, for-profit dialy-
sis clinics havebeen criticized for engaging inpractices aimed
to reducecostsor increase revenue, suchasusingshorter treat-
ments, less use of home dialysis, and encouraging fewer
transplantations,whichmay leadtopatientharm.4,5This study
demonstrates an additional mechanism through which
for-profit companies increase revenue.
There are several limitations. One or a handful of com-
mercial insurers may reimburse disproportionately, skewing
the payment difference identified. Second, there may be
errors in cost allocation. Using Medicare cost reports, Medi-
care’s PaymentAdvisory Committee estimated average treat-
mentcostsacrossdialysisprovidersat$243 in2016.2Thehigher
expenses reported by DaVita ($269) may reflect inaccuracies
in theMedicare cost reports or this company’s financial state-
ments.Finally, analyzing1company limitsgeneralizability.The
other major for-profit dialysis provider, Fresenius, does not
itemize revenuebypayer, but in2017 theirmeanNorthAmeri-
can revenue per treatment was $353, per treatment cost was
$282, and operating margin was 19%—similar to DaVita.6
Reducing payments from commercial insurers, perhaps
through increased competition or fixing charges at a percent
ofMedicare reimbursement,mayhelp alleviate excess spend-
ing on dialysis.
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